Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xeris Biopharma HoldingsSTU:2B30 +1.49%74 PB Ratio is 111.26 as of Jul. 15, 2026, which is 2065% above its 10-year median of 5.14. GuruFocus rates STU:2B30 with a GF Score™ of 74/100 and a GF Value™ of €4.55 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Xeris Biopharma Holdings ranks worse than 99.89% on this metric.
Xeris Biopharma Holdings Inc stock PB Ratio (=110.27) is close to 10-year high of 111.2.
The historical rank and industry rank for Xeris Biopharma Holdings's PB Ratio or its related term are showing as below:
STU:2B30'
s PB Ratio Range Over the Past 10 Years
Min: 2.14 Med: 5.14 Max: 111.2
Current: 110.27
During the past 10 years, Xeris Biopharma Holdings's highest PB Ratio was 111.20. The lowest was 2.14. And the median was 5.14.
STU:2B30's PB Ratio is ranked worse than 99.89% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs STU:2B30: 110.27
During the past 3 years, the average Book Value Per Share Growth Rate was -37.30% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Xeris Biopharma Holdings was -14.40% per year. The lowest was -40.50% per year. And the median was -37.30% per year.
Back to Basics: PB Ratio
Xeris Biopharma Holdings (STU:2B30) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Xeris Biopharma Holdings (STU:2B30) has a PB Ratio of 111.26 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Xeris Biopharma Holdings and its competitors. This is 2065% above median its historical median of 5.14. Over the past decade, Xeris Biopharma Holdings' PB Ratio has ranged from 2.14 to 111.20. According to the industry distribution chart, Xeris Biopharma Holdings ranks #921 out of 922 companies in the Drug Manufacturers industry, placing it in the top 99.9%.
Is Xeris Biopharma Holdings' PB Ratio too high?
Xeris Biopharma Holdings' current PB Ratio of 111.26 is 2065% above median its 10-year median of 5.14. Over the past 10 years, this metric has ranged from a low of 2.14 to a high of 111.20. The Drug Manufacturers industry median PB Ratio is 1.92. Xeris Biopharma Holdings' value of 111.26 is 5694.8% above this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #921 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Xeris Biopharma Holdings has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' PB Ratio compare to PAHC and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #921 out of 922 companies for PB Ratio. This places Xeris Biopharma Holdings in the lower half of its industry. The industry median PB Ratio is 1.92. Xeris Biopharma Holdings' value of 111.26 is 5694.8% above this benchmark. Historically, Xeris Biopharma Holdings' own PB Ratio has ranged from 2.14 to 111.20 over the past decade. While the company's 10-year median is 5.14 vs. the industry median of 1.92, Xeris Biopharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current PB Ratio of 111.26 is 5694.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Xeris Biopharma Holdings and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current PB Ratio is 111.26, which is 2065% above median its own 10-year median of 5.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (STU:2B30) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.55, compared to a current price of €7.23 — trading 58.9% above its estimated fair value. The current PB Ratio is 111.26, which is 2065% above median its 10-year median of 5.14 and 5694.8% above the Drug Manufacturers industry median of 1.92. Xeris Biopharma Holdings' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Xeris Biopharma Holdings (STU:2B30), the current PB Ratio is 111.26 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (STU:2B30) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of €7.23 is trading 58.9% above its estimated GF Value™ of €4.55.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for STU:2B30:
PB Ratio: 111.26 (2065% above median its 10-year median of 5.14)
GF Value™: €4.55 vs. price of €7.23 (58.9% above fair value)
Industry Position: 5694.8% above the Drug Manufacturers median (#921 of 922)
No single metric tells the full story. See the STU:2B30 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
74GF Score
Get the complete analysis for STU:2B30
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2B30 has been successfully added to your 
